The Preparation of an Acceptable Placebo for NPH Insulin
- Robert G Johnson, M.D., Ph.D.,
- John E Godine, M.D., Ph.D.,
- Katherine Hurxthal, R.N., M.P.H. and
- David M Nathan, M.D.
- Diabetes Unit and Medical Services, Massachusetts General Hospital; and the Department of Medicine, Harvard Medical School Boston, Massachusetts
- Address reprint requests to David M. Nathan, M.D., Diabetes Unit, Massachusetts General Hospital, Boston, Massachusetts 02114.
Abstract
A suitable placebo for NPH insulin has not previously been available for clinical investigation. A series of organic and inorganic compounds were formulated as insulin placebos and analyzed according to the following criteria: (1) degree of visual similarity to insulin, (2) stability, (3) absence of local side effects, and (4) clinical safety. Dilute suspensions of cortisone acetate (1.25–2.5 mg/ml) were found to fulfill the criteria as acceptable insulin placebos. Placebo-controlled studies with NPH insulin can now be performed.
- Copyright © 1985 by the American Diabetes Association
